Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Regulatory Approval

Every regulatory approval filing by a US-listed company that our alert engine sent, newest first.

9:25 AM ET 8-K
Regulatory Approval Edesa Biotech, Inc. EDSA

Edesa Biotech Regulatory Approval

Edesa Biotech announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (ARDS). The designation provides regulatory incentives including reduced development fees and potential market exclusivity for up to 10 years following approval.

Counterparty
European Commission
Term
10 years
9:19 AM ET 8-K
Regulatory Approval MiniMed Group, Inc. MMED

MiniMed Group Regulatory Approval

MiniMed Group received FDA clearance for its MiniMed Fit™ patch pump, the company's first tubeless insulin pump, several months ahead of schedule. The approval triggers a $162 million one-time R&D payment obligation and has led the company to accelerate its U.S. commercial launch to Spring 2027.

8:36 AM ET 8-K
Regulatory Approval Tandem Diabetes Care Inc TNDM

Tandem Diabetes Care Regulatory Approval

Tandem Diabetes Care received FDA 510(k) clearance for Tandem Mobi, the world's first and only tubeless automated insulin delivery system with up to 7 days of wear. The clearance allows the pump to offer both tubed and tubeless infusion options, with a full commercial launch planned for the first half of 2027.

4:46 PM ET 8-K
Regulatory Approval InspireMD, Inc. NSPR

InspireMD Regulatory Approval

InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. This approval doubles the company's total addressable market in the U.S., providing access to over 35,000 annual procedures with its proprietary MicroNet technology.

4:08 PM ET 8-K
Regulatory Approval Metagenomi Therapeutics, Inc. MGX

Metagenomi Therapeutics Regulatory Approval

Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.

“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”

Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
8:32 AM ET 8-K
Regulatory Approval Mmex Resources Corp MMEX

Mmex Resources Regulatory Approval

MMEX Resources' affiliate received approval from the Texas Commission on Environmental Quality (TCEQ) for its UltraClean Refinery North facility in Pecos County. This approval, combined with a previous approval for the South facility, enables a planned refinery complex with a processing capacity of 60,000 barrels of crude oil per day.

Counterparty
Texas Commission on Environmental Quality
6:04 AM ET 8-K
Regulatory Approval Bioxytran, Inc BIXT

Bioxytran Regulatory Approval

Bioxytran secured a government-issued Free Sale Certificate for its A-SUQAR chewable nutraceutical, a key regulatory milestone for market entry in the UAE and Gulf Cooperation Council region. The certification confirms the product is lawfully manufactured and sold as a health supplement, allowing the company to proceed with product registration in markets with high diabetes prevalence.

8:42 AM ET 8-K
Regulatory Approval Viking Global Technologies, Inc. VGTK

Viking Global Technologies Regulatory Approval

Viking Global Technologies' subsidiary, Viking Ozone Technology, received formal Attestation of Conformity No. 41506-0 from the French regulator LNE for its VKIN-300 medical waste pretreatment system. The approval confirms the ozone-based disinfection technology complies with French Standard NF X 30-503-1:2024, enabling commercialization of the system in France through October 2031.

Counterparty
Laboratoire national de métrologie et d'essais (LNE)
Term
5 years
8:06 AM ET 8-K
Regulatory Approval NRX Pharmaceuticals, Inc. NRXP

NRX Pharmaceuticals Regulatory Approval

NRx Pharmaceuticals received FDA approval for its Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine ahead of its November 10 goal date. The product is an American-manufactured formulation that eliminates the use of benzethonium chloride, a preservative the FDA has declined to designate as safe. The company aims to address the ongoing national shortage of ketamine using modern high-volume manufacturing technology in partnership with Nephron Pharmaceuticals.

“We are excited to bring Preservative-Free Ketamine to market and to give patients and their physicians an option for repeat treatments without the potential dangers of a preservative that has been classified as unacceptable for inclusion in multiple product categories by the US Food and Drug Administration.”

Jonathan Javitt, MD, MPH, the company’s Chairman and Chief Executive Officer
7:15 AM ET 8-K
Regulatory Approval Inovio Pharmaceuticals, Inc. INO

Inovio Pharmaceuticals Regulatory Approval

The FDA granted accelerated approval for INOVIO's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). This represents the first U.S. FDA-approved DNA medicine and validates INOVIO's platform technology, with a commercial launch expected in Q1 2027.

“With the approval of VOCERYQ, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option. VOCERYQ is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
8:47 AM ET 8-K
Regulatory Approval Processa Pharmaceuticals, Inc. PCSA

Processa Pharmaceuticals Regulatory Approval

Processa Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for VT-7208, allowing the company to initiate a Phase 2 study in patients with chronic spontaneous urticaria. The company also appointed Dr. Sheila Gujrathi as Executive Chair and entered into a research collaboration with Generian Pharmaceuticals to expand its pipeline.

6:03 AM ET 8-K
Regulatory Approval Supernus Pharmaceuticals, Inc. SUPN

Supernus Pharmaceuticals Regulatory Approval

The FDA has recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in advanced Parkinson’s disease. The exclusivity period is retroactive to the drug's approval date of February 3, 2025, and the company has also submitted an sNDA for a second supplier to ensure long-term supply stability.

Term
7 years

“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”

Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals
4:17 PM ET 8-K
Regulatory Approval Ionis Pharmaceuticals Inc IONS

Ionis Pharmaceuticals Regulatory Approval

Ionis Pharmaceuticals' partner GSK received FDA approval for HIBSAGO (bepirovirsen) for the treatment of chronic hepatitis B (CHB) in adult patients without cirrhosis. The approval, granted under priority review and Breakthrough Therapy Designation, is based on Phase 3 B-Well trials showing a 19% functional cure rate compared to less than 1% for standard of care. Ionis is eligible to receive regulatory and sales milestone payments plus tiered royalties of 10-12% on net sales.

Counterparty
GSK
5:19 PM ET 8-K
Regulatory Approval ImmunityBio, Inc. IBRX

ImmunityBio Regulatory Approval

The FDA has expanded the approved indication for ImmunityBio's ANKTIVA in combination with BCG to include patients with BCG-unresponsive NMIBC with papillary-only tumors. This follows the initial April 2024 approval and broadens the addressable patient population to include all patients with BCG-unresponsive NMIBC, a group that represents approximately 85% of the NMIBC population.

8:36 AM ET 8-K
Regulatory Approval SAB Biotherapeutics, Inc. SABS

SAB Biotherapeutics Regulatory Approval

SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.

8:39 AM ET 8-K
Regulatory Approval Vir Biotechnology, Inc. VIR

Vir Biotechnology Regulatory Approval

Vir Biotechnology announced that the FDA has granted Fast Track designation to VIR-5500, a PSMA-targeted T-cell engager being co-developed with Astellas Pharma for the treatment of metastatic castration-resistant prostate cancer. The designation is intended to expedite the development and review of the drug, which is currently in Phase 1 trials with Phase 3 development anticipated to begin in 2027.

Counterparty
Astellas Pharma Inc.
6:28 AM ET 8-K
Regulatory Approval Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Regulatory Approval

Perspective Therapeutics announced that the FDA has granted Fast Track Designation for PSV359, an investigational FAP-targeted alpha-particle therapy. The designation is for the treatment of adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors (SFTs).

6:11 AM ET 8-K
Regulatory Approval Lipocine Inc. LPCN

Lipocine Regulatory Approval

Lipocine announced that Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males. The product is licensed to Verity Pharmaceuticals, which plans to launch and commercialize the oral therapeutic in the Canadian market by the end of 2026.

Counterparty
Health Canada
4:30 PM ET 8-K
Regulatory Approval HeartSciences Inc. HSCS

HeartSciences Regulatory Approval

HeartSciences received FDA 510(k) clearance for its MyoVista wavECG device as a 12-lead resting electrocardiograph for adult and pediatric patients. While the company does not intend to commercialize the device without a cleared AI-ECG algorithm, the approval broadens strategic options for the asset and its intellectual property. The company also noted its pending merger with Fortitude Mining Holdings remains on track to close in Q4 2026.

5:07 PM ET 8-K
Regulatory Approval Equillium, Inc. EQ

Equillium Regulatory Approval

Equillium received clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification scheme to initiate a Phase 1 clinical trial of EQ504. The study will evaluate the safety and pharmacokinetics of the oral drug in healthy participants, with dosing expected to begin in early November 2026.

4:02 PM ET 8-K
Regulatory Approval Endovia Health Sciences, Inc. EDVA

Endovia Health Sciences Regulatory Approval

Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined its investigational drug CannEpil qualifies as a 'minor use' under the MUMS program for canine bone cancer pain. This designation allows the company to pursue a conditional approval pathway, which facilitates earlier market availability while additional effectiveness data is collected. The company is targeting a potential U.S. veterinary product launch in 2027.

Counterparty
Lupvindol BioSciences
8:05 AM ET 8-K
Regulatory Approval Tela Bio, Inc. TELA

Tela Bio Regulatory Approval

TELA Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This marks a significant milestone as it is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house.

“FDA 510(k) clearance is a significant milestone for TELA Bio as Liora is the first fully resorbable synthetic product in our portfolio to be designed and produced in-house by our team of innovative engineers.”

Heather Getz, CEO of TELA Bio
4:46 PM ET 8-K
Regulatory Approval American Battery Technology Co ABAT

American Battery Technology Regulatory Approval

American Battery Technology Company received an export license from the U.S. Department of Commerce for the sale of up to $100 million of recycled black mass material. This approval follows new federal export controls on critical battery materials and enables the company to scale its commercial recycling operations and global sales.

Counterparty
U.S. Department of Commerce, Bureau of Industry and Security
9:01 AM ET 8-K
Regulatory Approval NovoCure Ltd NVCR

NovoCure Regulatory Approval

NovoCure received approval from Japan's Ministry of Health, Labour and Welfare for its Optune Pax device to treat adult patients with unresectable locally advanced pancreatic cancer. The approval was based on Phase 3 PANOVA-3 trial results showing statistically significant improvement in median overall survival. This marks a major commercial milestone for the company in Japan, where pancreatic cancer is the fourth leading cause of cancer death.

Counterparty
Ministry of Health, Labour and Welfare (MHLW)
11:08 AM ET 8-K
Regulatory Approval CapsoVision, Inc CV

CapsoVision Regulatory Approval

CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus small bowel capsule endoscopy system. The tool is designed to reduce physician review time by automatically identifying and prioritizing images containing suspected abnormal lesions in patients with suspected small bowel bleeding.

8:04 AM ET 8-K
Regulatory Approval Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Regulatory Approval

The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. The drug, licensed from Incyte, is a first-of-its-kind oral ALK2 inhibitor designed to reduce new heterotopic ossification (abnormal bone formation). Mirum expects the product to be commercially available in the U.S. in October 2026.

Counterparty
Incyte Corporation
4:17 PM ET 8-K
Regulatory Approval Quoin Pharmaceuticals Ltd. QNRX

Quoin Pharmaceuticals Regulatory Approval

Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome. This is the first-ever Fast Track Designation granted for this rare genetic skin disease, which currently has no approved treatments. The company expects to initiate a Phase 2/3 clinical study for the indication in the second half of 2026.

4:15 PM ET 8-K
Regulatory Approval TriSalus Life Sciences, Inc. TLSI

TriSalus Life Sciences Regulatory Approval

TriSalus Life Sciences received FDA 510(k) clearance for its TriNav Advance device, an expansion of its Pressure-Enabled Drug Delivery (PEDD) portfolio. The device is designed to access small, distal vessels during liver embolization procedures and the company expects to commence commercialization in the coming weeks.

4:30 PM ET 8-K
Regulatory Approval NewAmsterdam Pharma Co N.V. NAMS

NewAmsterdam Pharma Co Regulatory Approval

NewAmsterdam Pharma and its partner Menarini Group received European Commission marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe FDC) for the treatment of hypercholesterolaemia, marking the first regulatory approval for obicetrapib worldwide. The approval triggers milestone payments to NewAmsterdam in the mid-teens of millions of euros under its existing licensing agreement with Menarini. The company remains eligible for up to €833 million in total milestones plus tiered double-digit royalties on net sales in Europe.

Counterparty
Menarini Group
3:57 PM ET 8-K
Regulatory Approval Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Regulatory Approval

The FDA has granted standard full approval for Ultragenyx's FAYUVI (rebisufligene etisparvovec-hopf), the first-ever approved treatment for Sanfilippo syndrome Type A (MPS IIIA). This marks the company's second gene therapy approval and resulted in the receipt of a Priority Review Voucher.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.